On March 24, REGENXBIO Inc. shared a Letter to the Duchenne Community announcing updates to their RGX-202 AFFINITY DUCHENNE gene therapy for the treatment of Duchenne muscular dystrophy.
To view their letter to the Duchenne community, please click here.